These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22147937)

  • 21. Impact of genetic markers on treatment of non-small cell lung cancer.
    Lamparella N; Barochia A; Almokadem S
    Adv Exp Med Biol; 2013; 779():145-64. PubMed ID: 23288638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
    Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
    Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
    Shepherd FA; Tsao MS
    J Clin Oncol; 2006 Mar; 24(7):1219-20; author reply 1220-1. PubMed ID: 16505443
    [No Abstract]   [Full Text] [Related]  

  • 24. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
    Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
    BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer.
    Leidinger P; Brefort T; Backes C; Krapp M; Galata V; Beier M; Kohlhaas J; Huwer H; Meese E; Keller A
    Oncotarget; 2016 Jan; 7(4):4611-23. PubMed ID: 26672767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biology and management of non-small cell lung cancer.
    Herbst RS; Morgensztern D; Boshoff C
    Nature; 2018 Jan; 553(7689):446-454. PubMed ID: 29364287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 28. MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human non-small cell lung caner.
    Shang Y; Zang A; Li J; Jia Y; Li X; Zhang L; Huo R; Yang J; Feng J; Ge K; Yang Y; Zhang Y; Jiang J
    Biomed Pharmacother; 2016 Oct; 83():1175-1181. PubMed ID: 27551765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Expression of microRNA let-7a, miR-155, and miR-205 in tumor and tumor-adjacent histologically normal tissue in patients with non-small cell lung cancer].
    Shikeeva AA; Kekeeva TV; Zavalishina LE; Andreeva YY; Zaletaev DV; Frank GA
    Arkh Patol; 2016; 78(3):3-10. PubMed ID: 27296000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection.
    Jiang W; Pang XG; Wang Q; Shen YX; Chen XK; Xi JJ
    Clin Lung Cancer; 2012 Jul; 13(4):280-7. PubMed ID: 22178381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pitfalls in the assessment of prognostic factors.
    Metze K
    Lancet Oncol; 2011 Nov; 12(12):1095-6. PubMed ID: 22041541
    [No Abstract]   [Full Text] [Related]  

  • 32. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer.
    Chuang JC; Liang Y; Wakelee HA
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):31-44. PubMed ID: 27912832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.
    Martin P; Leighl NB; Tsao MS; Shepherd FA
    J Thorac Oncol; 2013 May; 8(5):530-42. PubMed ID: 23524403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic Evaluation of Diabetes and Local Recurrence in Non-Small Cell Lung Cancer.
    Yang X; Liu Y; Mani H; Olson J; Clawson G; Caruso C; Bruggeman R; Varlotto JM; Zander DS; Rassaei N
    Pathol Oncol Res; 2017 Jan; 23(1):73-77. PubMed ID: 27411924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer.
    Duan MC; Han W; Jin PW; Wei YP; Wei Q; Zhang LM; Li JC
    Inflammation; 2015 Dec; 38(6):2156-65. PubMed ID: 26077695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long non-coding RNA as potential biomarkers in non-small-cell lung cancer: What do we know so far?
    Osielska MA; Jagodziński PP
    Biomed Pharmacother; 2018 May; 101():322-333. PubMed ID: 29499406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
    Ai B; Liu H; Huang Y; Peng P
    Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients.
    Geng JQ; Wang XC; Li LF; Zhao J; Wu S; Yu GP; Zhu KJ
    Tumour Biol; 2016 Feb; 37(2):2257-65. PubMed ID: 26358254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.